Senescent cells: an emerging target for diseases of ageing

Key Points

  • Cellular senescence is a tumour-suppressive fate by which damaged cells permanently withdraw from the cell cycle and acquire a distinct secretome.

  • A variety of age-related diseases as well as beneficial, normal processes have been linked to either senescence arrest or to factors released in the senescent cell (SNC) secretome in recent years.

  • Evidence for a potential role of SNCs in major diseases, including osteoarthritis, atherosclerosis and cancer, has sparked interest in the development of senotherapies, treatments aimed at neutralizing the disease-causing features of SNCs.

  • One main senotherapeutic strategy is senolysis in which drugs (senolytics) are used to specifically and efficiently kill SNCs. First-generation senolytics generally act by inhibiting pro-survival adaptations that SNCs use to resist apoptosis and have shown efficacy against atherosclerosis, osteoarthritis and other age-related diseases.

  • Inhibition of the senescence-associated secretory phenotype (SASP) may be another useful senotherapy, but — in contrast to senolysis — this would likely require continuous dosing, whereas SNC killing could be carried out intermittently.

  • Senotherapy is a promising new approach to treating age-related diseases, but successfully translating this to the clinic will require new methods for evaluating SNC burden in humans, a clear mechanistic understanding of the link between senescence and disease and proof that senotherapy is safe.

Abstract

Chronological age represents the single greatest risk factor for human disease. One plausible explanation for this correlation is that mechanisms that drive ageing might also promote age-related diseases. Cellular senescence, which is a permanent state of cell cycle arrest induced by cellular stress, has recently emerged as a fundamental ageing mechanism that also contributes to diseases of late life, including cancer, atherosclerosis and osteoarthritis. Therapeutic strategies that safely interfere with the detrimental effects of cellular senescence, such as the selective elimination of senescent cells (SNCs) or the disruption of the SNC secretome, are gaining significant attention, with several programmes now nearing human clinical studies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Timeline of milestones relevant to senotherapy.
Figure 2: Hallmarks of SNCs.
Figure 3: Preclinical testing of senolytic candidates.

References

  1. 1

    Weismann, A. Collected Essays upon Heredity and Kindred Biological Problems (ed. Poulton, E. B.) (Clarendon, 1881).

  2. 2

    Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961). First detection of cellular senescence in vitro.

  3. 3

    Campisi, J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 75, 685–705 (2013).

  4. 4

    Munoz-Espin, D. & Serrano, M. Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15, 482–496 (2014).

  5. 5

    van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014).

  6. 6

    Sharpless, N. E. & Sherr, C. J. Forging a signature of in vivo senescence. Nat. Rev. Cancer 15, 397–408 (2015). This review comprehensively examined the question of SNC detection, quantification and identification in vivo , and is an excellent resource for new investigators to the field.

  7. 7

    Baker, D. J. et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016). This is a first demonstration that SNCs reduce lifespan and negatively impact healthspan in naturally-aged, non-progeroid mice.

  8. 8

    Jeon, O. H. et al. Clearance of senescent cells prevents the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat. Med. 23, 775–781 (2017).

  9. 9

    Baker, D. J. et al. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat. Cell Biol. 10, 825–836 (2008).

  10. 10

    Baker, D. J. et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232–236 (2011). Proof-of-concept study for transgene-mediated SNC killing and first demonstration that removing SNCs once they arise extends healthspan in vivo.

  11. 11

    Childs, B. G. et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 354, 472–477 (2016). This study links the pro-inflammatory, proteolytic properties of plaque SNCs to progression and destabilization of atherosclerosis.

  12. 12

    Munoz-Espin, D. et al. Programmed cell senescence during mammalian embryonic development. Cell 155, 1104–1118 (2013).

  13. 13

    Mosteiro, L. et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science 354, aaf4445 (2016).

  14. 14

    Storer, M. et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 155, 1119–1130 (2013). References 12 and 14 show that cellular senescence contributes to tissue patterning during mammalian embryogenesis.

  15. 15

    Demaria, M. et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell 31, 722–733 (2014).

  16. 16

    Chuprin, A. et al. Cell fusion induced by ERVWE1 or measles virus causes cellular senescence. Genes Dev. 27, 2356–2366 (2013).

  17. 17

    Li, T. et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269–1283 (2012).

  18. 18

    Helman, A. et al. p16Ink4a-induced senescence of pancreatic beta cells enhances insulin secretion. Nat. Med. 22, 412–420 (2016).

  19. 19

    Rudin, C. M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163–3169 (2012).

  20. 20

    Laberge, R. M. et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol. 17, 1049–1061 (2015). This study provides proof of concept that the inflammatory SNC secretory phenotype could be pharmacologically inhibited using an approved drug (rapamycin).

  21. 21

    Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78–83 (2016). First demonstration that pharmacological inhibition of anti-apoptotic BCL-2 family members shows senescent cell killing (senolytic) activity.

  22. 22

    Wang, Y. et al. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. Aging 8, 2915–2926 (2016).

  23. 23

    Zhu, Y. et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644–658 (2015).

  24. 24

    Yosef, R. et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 7, 11190 (2016).

  25. 25

    Karatza, C., Stein, W. D. & Shall, S. Kinetics of in vitro ageing of mouse embryo fibroblasts. J. Cell Sci. 65, 163–175 (1984).

  26. 26

    Ponten, J., Stein, W. D. & Shall, S. A quantitative analysis of the aging of human glial cells in culture. J. Cell. Physiol. 117, 342–352 (1983).

  27. 27

    Cristofalo, V. J. & Sharf, B. B. Cellular senescence and DNA synthesis. Thymidine incorporation as a measure of population age in human diploid cells. Exp. Cell Res. 76, 419–427 (1973).

  28. 28

    Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614–636 (1965).

  29. 29

    Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995). This study reports the development of the SA- β -Gal stain, which is a widely used biomarker for detecting SNCs in vitro and in vivo.

  30. 30

    Serrano, M., Hannon, G. J. & Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704–707 (1993).

  31. 31

    Alcorta, D. A. et al. Involvement of the cyclin-dependent kinase inhibitor p16INK4a in replicative senescence of normal human fibroblasts. Proc. Natl Acad. Sci. USA 93, 13742–13747 (1996).

  32. 32

    Serrano, M. et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27–37 (1996).

  33. 33

    Beausejour, C. M. et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22, 4212–4222 (2003).

  34. 34

    Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725–730 (2005). This is a first example of a loss of tumour suppressor function (PTEN insufficiency), which results in cellular senescence.

  35. 35

    Evangelou, K. et al. Robust, universal biomarker assay to detect senescent cells in biological specimens. Aging Cell 16, 192–197 (2017).

  36. 36

    Minamino, T. et al. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 105, 1541–1544 (2002).

  37. 37

    Krishnamurthy, J. et al. Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 114, 1299–1307 (2004).

  38. 38

    Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997).

  39. 39

    Aguilera, A. & Garcia-Muse, T. Causes of genome instability. Annu. Rev. Genet. 47, 1–32 (2013).

  40. 40

    Davoli, T., Denchi, E. L. & de Lange, T. Persistent telomere damage induces bypass of mitosis and tetraploidy. Cell 141, 81–93 (2010).

  41. 41

    Coppe, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853–2868 (2008).

  42. 42

    Coppe, J. P. et al. A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS ONE 5, e9188 (2010).

  43. 43

    Rodier, F. et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 11, 973–979 (2009).

  44. 44

    Rodier, F. et al. DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J. Cell Sci. 124, 68–81 (2011).

  45. 45

    Sturmlechner, I., Durik, M., Sieben, C. J., Baker, D. J. & van Deursen, J. M. Cellular senescence in renal ageing and disease. Nat. Rev. Nephrol. 13, 77–89 (2017).

  46. 46

    Childs, B. G., Durik, M., Baker, D. J. & van Deursen, J. M. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat. Med. 21, 1424–1435 (2015).

  47. 47

    Alimonti, A. et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 120, 681–693 (2010).

  48. 48

    Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637 (2006).

  49. 49

    Pluquet, O., Pourtier, A. & Abbadie, C. The unfolded protein response and cellular senescence. A review in the theme: cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. Am. J. Physiol. Cell Physiol. 308, C415–C425 (2015).

  50. 50

    Shiloh, Y. & Ziv, Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14, 197–210 (2013).

  51. 51

    Eischen, C. M. & Lozano, G. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum. Mutat. 35, 728–737 (2014).

  52. 52

    Herbig, U., Wei, W., Dutriaux, A., Jobling, W. A. & Sedivy, J. M. Real-time imaging of transcriptional activation in live cells reveals rapid up-regulation of the cyclin-dependent kinase inhibitor gene CDKN1A in replicative cellular senescence. Aging Cell 2, 295–304 (2003).

  53. 53

    Wong, E. S. et al. p38MAPK controls expression of multiple cell cycle inhibitors and islet proliferation with advancing age. Dev. Cell 17, 142–149 (2009).

  54. 54

    Ohtani, N. et al. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409, 1067–1070 (2001).

  55. 55

    Takahashi, A. et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat. Cell Biol. 8, 1291–1297 (2006).

  56. 56

    Johmura, Y. et al. Necessary and sufficient role for a mitosis skip in senescence induction. Mol. Cell 55, 73–84 (2014).

  57. 57

    Le, O. N. et al. Ionizing radiation-induced long-term expression of senescence markers in mice is independent of p53 and immune status. Aging Cell 9, 398–409 (2010).

  58. 58

    Acosta, J. C. et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006–1018 (2008).

  59. 59

    Kuilman, T. et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019–1031 (2008). References 41, 58 and 59 established that the secretory profile of SNCs is a hallmark of this cell type.

  60. 60

    Acosta, J. C. et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 15, 978–990 (2013).

  61. 61

    Kuilman, T. & Peeper, D. S. Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer 9, 81–94 (2009).

  62. 62

    Campisi, J. & d'Adda di Fagagna, F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729–740 (2007).

  63. 63

    Freund, A., Patil, C. K. & Campisi, J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 30, 1536–1548 (2011).

  64. 64

    Hoare, M. et al. NOTCH1 mediates a switch between two distinct secretomes during senescence. Nat. Cell Biol. 18, 979–992 (2016). This study demonstrated that the SNC secretory profile changes composition over time to coordinate distinct paracrine signalling events to immune cells and surrounding tissue.

  65. 65

    Orjalo, A. V., Bhaumik, D., Gengler, B. K., Scott, G. K. & Campisi, J. Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc. Natl Acad. Sci. USA 106, 17031–17036 (2009).

  66. 66

    Eyman, D., Damodarasamy, M., Plymate, S. R. & Reed, M. J. CCL5 secreted by senescent aged fibroblasts induces proliferation of prostate epithelial cells and expression of genes that modulate angiogenesis. J. Cell. Physiol. 220, 376–381 (2009).

  67. 67

    Luo, X. et al. Stromal-initiated changes in the bone promote metastatic niche development. Cell Rep. 14, 82–92 (2016).

  68. 68

    Angelini, P. D. et al. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Res. 73, 6095–6095 (2013).

  69. 69

    Ruhland, M. K. et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat. Commun. 7, 11762 (2016).

  70. 70

    Eggert, T. et al. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer Cell 30, 533–547 (2016).

  71. 71

    Ritschka, B. et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev. 31, 172–183 (2017). This work implicated signals arising from the SNC secretome to stemness during tissue regeneration.

  72. 72

    Inoue, K. et al. Serial coronary CT angiography-verified changes in plaque characteristics as an end point: evaluation of effect of statin intervention. JACC Cardiovasc. Imaging 3, 691–698 (2010).

  73. 73

    Eren, M. et al. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proc. Natl Acad. Sci. USA 111, 7090–7095 (2014).

  74. 74

    Liu, D. & Hornsby, P. J. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res. 67, 3117–3126 (2007).

  75. 75

    Childs, B. G., Baker, D. J., Kirkland, J. L., Campisi, J. & van Deursen, J. M. Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. 15, 1139–1153 (2014). This review gives a broad overview of the possible advantages of senescence compared with apoptosis as a fate for damaged cells.

  76. 76

    Burton, D. G. & Faragher, R. G. Cellular senescence: from growth arrest to immunogenic conversion. Age (Dordr.) 37, 27 (2015).

  77. 77

    Tavana, O. et al. Absence of p53-dependent apoptosis leads to UV radiation hypersensitivity, enhanced immunosuppression and cellular senescence. Cell Cycle 9, 3328–3336 (2010).

  78. 78

    Webley, K. et al. Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol. Cell. Biol. 20, 2803–2808 (2000).

  79. 79

    Timofeev, O. et al. p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo. Cell Rep. 3, 1512–1525 (2013).

  80. 80

    Zhang, Y. et al. DNMT3a plays a role in switches between doxorubicin-induced senescence and apoptosis of colorectal cancer cells. Int. J. Cancer 128, 551–561 (2011).

  81. 81

    Hayward, R. L. et al. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin. Cancer Res. 9, 2856–2865 (2003).

  82. 82

    Tang, J. J., Shen, C. & Lu, Y. J. Requirement for pre-existing of p21 to prevent doxorubicin-induced apoptosis through inhibition of caspase-3 activation. Mol. Cell. Biochem. 291, 139–144 (2006).

  83. 83

    Hanks, S. et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat. Genet. 36, 1159–1161 (2004).

  84. 84

    Donehower, L. A. The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer Biol. 7, 269–278 (1996).

  85. 85

    Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A. & Berns, A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413, 83–86 (2001).

  86. 86

    Schafer, M. J. et al. Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun. 8, 14532 (2017).

  87. 87

    Kang, T. W. et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547–551 (2011). This work demonstrates that the anticancer effects of cellular senescence extend beyond cell cycle arrest, in particular that SNCs may promote recruitment of tumour-suppressive immune effectors.

  88. 88

    Krtolica, A., Parrinello, S., Lockett, S., Desprez, P. Y. & Campisi, J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA 98, 12072–12077 (2001). This study provided early support for the hypothesis that SNCs promote carcinogenesis in a cell non-autonomous fashion.

  89. 89

    Bar-Shai, A., Sagiv, A., Alon, R. & Krizhanovsky, V. The role of Clara cell senescence in the pathogenesis of COPD. Eur. Respir. J. 44, 3245 (2014).

  90. 90

    Bhat, R. et al. Astrocyte senescence as a component of Alzheimer's disease. PLoS ONE 7, e45069 (2012).

  91. 91

    Demaria, M. et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 7, 165–176 (2017).

  92. 92

    Freund, A., Laberge, R. M., Demaria, M. & Campisi, J. Lamin B1 loss is a senescence-associated biomarker. Mol. Biol. Cell 23, 2066–2075 (2012).

  93. 93

    Laberge, R. M. et al. Mitochondrial DNA damage induces apoptosis in senescent cells. Cell Death Dis. 4, e727 (2013).

  94. 94

    Demaria, M., Desprez, P. Y., Campisi, J. & Velarde, M. C. Cell autonomous and non-autonomous effects of senescent cells in the skin. J. Invest. Dermatol. 135, 1722–1726 (2015).

  95. 95

    Roberts, S., Evans, E. H., Kletsas, D., Jaffray, D. C. & Eisenstein, S. M. Senescence in human intervertebral discs. Eur. Spine J. 15 (Suppl. 3), S312–S316 (2006).

  96. 96

    Le Maitre, C. L., Freemont, A. J. & Hoyland, J. A. Accelerated cellular senescence in degenerate intervertebral discs: a possible role in the pathogenesis of intervertebral disc degeneration. Arthritis Res. Ther. 9, R45 (2007).

  97. 97

    Sousa-Victor, P. et al. Geriatric muscle stem cells switch reversible quiescence into senescence. Nature 506, 316–321 (2014).

  98. 98

    Cosgrove, B. D. et al. Rejuvenation of the muscle stem cell population restores strength to injured aged muscles. Nat. Med. 20, 255–264 (2014).

  99. 99

    Bernet, J. D. et al. p38 MAPK signaling underlies a cell-autonomous loss of stem cell self-renewal in skeletal muscle of aged mice. Nat. Med. 20, 265–271 (2014).

  100. 100

    Du, J. et al. Aging increases CCN1 expression leading to muscle senescence. Am. J. Physiol. Cell Physiol. 306, C28–C36 (2014).

  101. 101

    Finn, A. V., Nakano, M., Narula, J., Kolodgie, F. D. & Virmani, R. Concept of vulnerable/unstable plaque. Arterioscler. Thromb. Vasc. Biol. 30, 1282–1292 (2010).

  102. 102

    Tabas, I., Garcia-Cardena, G. & Owens, G. K. Recent insights into the cellular biology of atherosclerosis. J. Cell Biol. 209, 13–22 (2015).

  103. 103

    Weber, C. & Noels, H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 17, 1410–1422 (2011).

  104. 104

    Berenbaum, F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 21, 16–21 (2013).

  105. 105

    Wieland, H. A., Michaelis, M., Kirschbaum, B. J. & Rudolphi, K. A. Osteoarthritis — an untreatable disease? Nat. Rev. Drug Discov. 4, 331–344 (2005).

  106. 106

    Lawrence, R. C. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 58, 26–35 (2008).

  107. 107

    March, L., Amatya, B., Osborne, R. H. & Brand, C. Developing a minimum standard of care for treating people with osteoarthritis of the hip and knee. Best Pract. Res. Clin. Rheumatol. 24, 121–145 (2010).

  108. 108

    Krizhanovsky, V. et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134, 657–667 (2008). This work shows a beneficial function (fibrosis restriction) for cellular senescence beyond tumour suppression.

  109. 109

    Luna-Vargas, M. P. & Chipuk, J. E. Physiological and pharmacological control of BAK, BAX, and beyond. Trends Cell Biol. 26, 906–917 (2016).

  110. 110

    Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421–3428 (2008).

  111. 111

    Zhu, Y. et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428–435 (2016).

  112. 112

    Bai, L. & Wang, S. Targeting apoptosis pathways for new cancer therapeutics. Annu. Rev. Med. 65, 139–155 (2014).

  113. 113

    Weisberg, E., Manley, P. W., Cowan-Jacob, S. W., Hochhaus, A. & Griffin, J. D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7, 345–356 (2007).

  114. 114

    Boots, A. W., Haenen, G. R. & Bast, A. Health effects of quercetin: from antioxidant to nutraceutical. Eur. J. Pharmacol. 585, 325–337 (2008).

  115. 115

    Chondrogianni, N. et al. Anti-ageing and rejuvenating effects of quercetin. Exp. Gerontol. 45, 763–771 (2010).

  116. 116

    Baar, M. P. et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 169, 132–147.e16 (2017).

  117. 117

    Roos, C. M. et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 15, 973–977 (2016).

  118. 118

    Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71–75 (2013).

  119. 119

    Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007). This work tested and validated the hypothesis that SNCs can be removed by the immune system and provided support for the idea that the SNC secretome drives this immune surveillance.

  120. 120

    Vindrieux, D. et al. Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis. Cancer Cell Int. 11, 42 (2011).

  121. 121

    Zhang, Z., Rosen, D. G., Yao, J. L., Huang, J. & Liu, J. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Mod. Pathol. 19, 1339–1343 (2006).

  122. 122

    Aydin, C. et al. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. Hum. Gene Ther. 18, 39–50 (2007).

  123. 123

    Wu, Q. et al. Aberrant expression of decoy receptor 3 in human breast cancer: relevance to lymphangiogenesis. J. Surg. Res. 188, 459–465 (2014).

  124. 124

    Ge, Z., Sanders, A. J., Ye, L. & Jiang, W. G. Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer. Exp. Ther. Med. 2, 167–172 (2011).

  125. 125

    Sagiv, A. et al. Granule exocytosis mediates immune surveillance of senescent cells. Oncogene 32, 1971–1977 (2013).

  126. 126

    Boivin, W. A., Cooper, D. M., Hiebert, P. R. & Granville, D. J. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab. Invest. 89, 1195–1220 (2009).

  127. 127

    Collado, M. & Serrano, M. Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer 10, 51–57 (2010).

  128. 128

    He, J., Hu, Y., Hu, M. & Li, B. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci. Rep. 5, 13110 (2015).

  129. 129

    Konkel, J. E. et al. PD-1 signalling in CD4+ T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance. Immunology 130, 92–102 (2010).

  130. 130

    Yang, G. et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl Acad. Sci. USA 103, 16472–16477 (2006).

  131. 131

    Elzi, D. J. et al. Plasminogen activator inhibitor 1—insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence. Proc. Natl Acad. Sci. USA 109, 12052–12057 (2012).

  132. 132

    Chien, Y. et al. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev. 25, 2125–2136 (2011).

  133. 133

    Baroja-Mazo, A., Revilla-Nuin, B., Ramirez, P. & Pons, J. A. Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation. World J. Transplant. 6, 183–192 (2016).

  134. 134

    Capell, B. C. et al. MLL1 is essential for the senescence-associated secretory phenotype. Genes Dev. 30, 321–336 (2016).

  135. 135

    Tasdemir, N. et al. BRD4 connects enhancer remodeling to senescence immune surveillance. Cancer Discov. 6, 612–629 (2016).

  136. 136

    Aird, K. M. et al. HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci. J. Cell Biol. 215, 325–334 (2016).

  137. 137

    Kojima, H., Inoue, T., Kunimoto, H. & Nakajima, K. IL-6-STAT3 signaling and premature senescence. JAK-STAT 2, e25763 (2013).

  138. 138

    Lee, S. et al. A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation. Nat. Chem. Biol. 10, 1055–1060 (2014).

  139. 139

    Lehmann, B. D. et al. Senescence-associated exosome release from human prostate cancer cells. Cancer Res. 68, 7864–7871 (2008).

  140. 140

    Xin, M. G., Zhang, J., Block, E. R. & Patel, J. M. Senescence-enhanced oxidative stress is associated with deficiency of mitochondrial cytochrome c oxidase in vascular endothelial cells. Mech. Ageing Dev. 124, 911–919 (2003).

  141. 141

    Effenberger, T. et al. Senescence-associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding. FASEB J. 28, 4847–4856 (2014).

  142. 142

    Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W. & Raulet, D. H. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J. Exp. Med. 210, 2057–2069 (2013).

  143. 143

    Rovillain, E. et al. Activation of nuclear factor-kappa B signalling promotes cellular senescence. Oncogene 30, 2356–2366 (2011).

  144. 144

    Afonina, I. S., Muller, C., Martin, S. J. & Beyaert, R. Proteolytic processing of interleukin-1 family cytokines: variations on a common theme. Immunity 42, 991–1004 (2015).

  145. 145

    McCarthy, D. A., Clark, R. R., Bartling, T. R., Trebak, M. & Melendez, J. A. Redox control of the senescence regulator interleukin-1alpha and the secretory phenotype. J. Biol. Chem. 288, 32149–32159 (2013).

  146. 146

    McQuibban, G. A. et al. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100, 1160–1167 (2002).

  147. 147

    van Rhee, F. et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 15, 966–974 (2014).

  148. 148

    Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516–1523 (2008).

  149. 149

    Mobasheri, A., Bay-Jensen, A. C., van Spil, W. E., Larkin, J. & Levesque, M. C. Osteoarthritis year in review 2016: biomarkers (biochemical markers). Osteoarthritis Cartilage 25, 199–208 (2017).

  150. 150

    Fernandez-Puente, P. et al. Identification of a panel of novel serum osteoarthritis biomarkers. J. Proteome Res. 10, 5095–5101 (2011).

  151. 151

    Kraus, V. B. et al. OARSI clinical trials recommendations: soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis Cartilage 23, 686–697 (2015).

  152. 152

    Bay-Jensen, A. C. et al. Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria. Osteoarthritis Cartilage 24, 9–20 (2016).

  153. 153

    Ahmed, U. et al. Biomarkers of early stage osteoarthritis, rheumatoid arthritis and musculoskeletal health. Sci. Rep. 5, 9259 (2015).

  154. 154

    Schwarzenbach, H., Hoon, D. S. B. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426–437 (2011).

  155. 155

    Agostini, A. et al. Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles. Angew. Chem. Int. Ed. 51, 10556–10560 (2012).

  156. 156

    Polakis, P. Antibody drug conjugates for cancer therapy. Pharmacol. Rev. 68, 3–19 (2016).

  157. 157

    Frescas, D. et al. Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody. Proc. Natl Acad. Sci. USA 114, E1668–E1677 (2017).

  158. 158

    Collado, M. et al. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005).

  159. 159

    Althubiti, M. et al. Characterization of novel markers of senescence and their prognostic potential in cancer. Cell Death Dis. 5, e1528 (2014).

  160. 160

    Kaefer, A. et al. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother. Pharmacol. 74, 593–602 (2014).

  161. 161

    Sharpless, N. E. et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413, 86–91 (2001). This is an important demonstration of the tumour-suppressive properties of a key senescence effector, p16INK4A.

  162. 162

    Barzilai, N., Crandall, J. P., Kritchevsky, S. B. & Espeland, M. A. Metformin as a tool to target aging. Cell Metab. 23, 1060–1065 (2016).

  163. 163

    Jun, J. I. & Lau, L. F. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat. Cell Biol. 12, 676–685 (2010).

  164. 164

    Sharpless, N. E., Ramsey, M. R., Balasubramanian, P., Castrillon, D. H. & DePinho, R. A. The differential impact of p16INK4a or p19ARF deficiency on cell growth and tumorigenesis. Oncogene 23, 379–385 (2004).

  165. 165

    Cairns, P. et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet. 11, 210–212 (1995).

  166. 166

    Herman, J. G. et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55, 4525–4530 (1995).

  167. 167

    Merlo, A. et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1, 686–692 (1995).

  168. 168

    Khanna, A. K. Enhanced susceptibility of cyclin kinase inhibitor p21 knockout mice to high fat diet induced atherosclerosis. J. Biomed. Sci. 16, 66 (2009).

  169. 169

    Visel, A. et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 464, 409–412 (2010).

  170. 170

    Chiche, A. et al. Injury-induced senescence enables in vivo reprogramming in skeletal muscle. Cell Stem Cell 20, 407–414.e4 (2017).

  171. 171

    Guan, X. et al. Stromal senescence by prolonged CDK4/6 inhibition potentiates tumor growth. Mol. Cancer Res. 15, 237–249 (2017).

  172. 172

    Cheung-Ong, K., Giaever, G. & Nislow, C. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem. Biol. 20, 648–659 (2013).

  173. 173

    Yeh, C. K. Cellular senescence and aging. Oral Dis. 22, 587–590 (2016).

  174. 174

    Oeffinger, K. C. et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355, 1572–1582 (2006).

  175. 175

    Schuitema, I. et al. Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. J. Clin. Oncol. 31, 3378–3388 (2013).

  176. 176

    Dorth, J. A., Patel, P. R., Broadwater, G. & Brizel, D. M. Incidence and risk factors of significant carotid artery stenosis in asymptomatic survivors of head and neck cancer after radiotherapy. Head Neck 36, 215–219 (2014).

  177. 177

    Anzidei, M. et al. Longitudinal assessment of carotid atherosclerosis after radiation therapy using computed tomography: a case control Study. Eur. Radiol. 26, 72–78 (2016).

  178. 178

    Wildiers, H. et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J. Clin. Oncol. 32, 2595–2603 (2014).

  179. 179

    Yip, C. et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur. Radiol. 24, 998–1005 (2014).

  180. 180

    Armstrong, G. T. et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J. Clin. Oncol. 32, 1218–1227 (2014).

  181. 181

    Coppe, J. P. et al. Tumor suppressor and aging biomarker p16INK4a induces cellular senescence without the associated inflammatory secretory phenotype. J. Biol. Chem. 286, 36396–36403 (2011). This work clearly demonstrated the separability of the SNC secretome from cell cycle arrest.

  182. 182

    Lan, L. et al. Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice. EMBO J. 34, 2383 (2015).

  183. 183

    Serrano, M. SHP2: a new target for pro-senescence cancer therapies. EMBO J. 34, 1439–1441 (2015).

  184. 184

    Fukazawa, R. et al. Coronary artery aneurysm induced by Kawasaki disease in children show features typical senescence. Circ. J. 71, 709–715 (2007).

  185. 185

    Liton, P. B. et al. Cellular senescence in the glaucomatous outflow pathway. Exp. Gerontol. 40, 745–748 (2005).

  186. 186

    Zhu, D., Wu, J., Spee, C., Ryan, S. J. & Hinton, D. R. BMP4 mediates oxidative stress-induced retinal pigment epithelial cell senescence and is overexpressed in age-related macular degeneration. J. Biol. Chem. 284, 9529–9539 (2009).

  187. 187

    Mishima, K. et al. Senescence-associated beta-galactosidase histochemistry for the primate eye. Invest. Ophthalmol. Vis. Sci. 40, 1590–1593 (1999).

  188. 188

    Sohn, J. J. et al. Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease. PLoS ONE 7, e44156 (2012).

  189. 189

    Martin, J. A., Brown, T. D., Heiner, A. D. & Buckwalter, J. A. Chondrocyte senescence, joint loading and osteoarthritis. Clin. Orthop. Relat. Res. 427 (Suppl.), S96–S103 (2004).

  190. 190

    Yanai, H. et al. Cellular senescence-like features of lung fibroblasts derived from idiopathic pulmonary fibrosis patients. Aging 7, 664–672 (2015).

  191. 191

    Aoshiba, K., Tsuji, T. & Nagai, A. Bleomycin induces cellular senescence in alveolar epithelial cells. Eur. Respir. J. 22, 436–443 (2003).

  192. 192

    Aoshiba, K. et al. Senescence-associated secretory phenotype in a mouse model of bleomycin-induced lung injury. Exp. Toxicol. Pathol. 65, 1053–1062 (2013).

  193. 193

    Fischer, B. M. et al. Increased expression of senescence markers in cystic fibrosis airways. Am. J. Physiol. Lung Cell. Mol. Physiol. 304, L394–L400 (2013).

  194. 194

    Markowski, D. N. et al. HMGA2 expression in white adipose tissue linking cellular senescence with diabetes. Genes Nutr. 8, 449–456 (2013).

  195. 195

    Minamino, T. et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat. Med. 15, 1082–1087 (2009).

  196. 196

    Fitzner, B. et al. Senescence determines the fate of activated rat pancreatic stellate cells. J. Cell. Mol. Med. 16, 2620–2630 (2012).

  197. 197

    Morgan, R. G. et al. Role of arterial telomere dysfunction in hypertension: relative contributions of telomere shortening and telomere uncapping. J. Hypertension 32, 1293–1299 (2014).

  198. 198

    Mercer, J., Figg, N., Stoneman, V., Braganza, D. & Bennett, M. R. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ. Res. 96, 667–674 (2005).

  199. 199

    Diez-Juan, A. & Andres, V. The growth suppressor p27(Kip1) protects against diet-induced atherosclerosis. FASEB J. 15, 1989–1995 (2001).

  200. 200

    Baker, D. J., Weaver, R. L. & van Deursen, J. M. p21 both attenuates and drives senescence and aging in BubR1 progeroid mice. Cell Rep. 3, 1164–1174 (2013).

  201. 201

    Braun, H. et al. Cellular senescence limits regenerative capacity and allograft survival. J. Am. Soc. Nephrol. 23, 1467–1473 (2012).

  202. 202

    Zhu, F. et al. Senescent cardiac fibroblast is critical for cardiac fibrosis after myocardial infarction. PLoS ONE 8, e74535 (2013).

  203. 203

    Shivshankar, P. et al. Caveolin-1 deficiency protects from pulmonary fibrosis by modulating epithelial cell senescence in mice. Am. J. Respir. Cell Mol. Biol. 47, 28–36 (2012).

  204. 204

    Li, H. et al. FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging. J. Clin. Invest. 127, 1241–1253 (2017).

  205. 205

    Green, D. R. A. BH3 mimetic for killing cancer cells. Cell 165, 1560 (2016).

  206. 206

    Maruthur, N. M. et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med. 164, 740–751 (2016).

  207. 207

    Moiseeva, O. et al. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kappaB activation. Aging Cell 12, 489–498 (2013).

  208. 208

    Noren Hooten, N. et al. Metformin-mediated increase in DICER1 regulates microRNA expression and cellular senescence. Aging Cell 15, 572–581 (2016).

  209. 209

    Webster, A. C., Lee, V. W., Chapman, J. R. & Craig, J. C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81, 1234–1248 (2006).

  210. 210

    Jobanputra, P., Barton, P., Bryan, S. & Burls, A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess. 6, 1–110 (2002).

  211. 211

    Kuemmerle-Deschner, J. B. et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res. Ther. 13, R34 (2011).

  212. 212

    Hoffman, H. M. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443–2452 (2008).

  213. 213

    Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675–681 (2004).

  214. 214

    Cohen, S. et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 614–624 (2002).

Download references

Acknowledgements

The authors thank N.David and Y.Poon of Unity Biotechnology for invaluable intellectual contributions to this Review and for thoroughly editing the text, and C.Yohn for feedback on the manuscript. The writing of this Review was supported by a grant from the Paul F.Glenn Foundation (J.M.v.D. and D.J.B.) and US National Institutes of Health (NIH) grants R01CA96985 and CA168709 (J.M.v.D.).

Author information

Correspondence to Jan M. van Deursen.

Ethics declarations

Competing interests

J.M.v.D. is a cofounder of Unity Biotechnology, which is a company developing senolytic medicines, including small molecules that selectively eliminate senescent cells. R.M.L., J.M.v.D., D.J.B. and B.G.C. are co-inventors on patent applications licensed to or filed by Unity Biotechnology. R.M.L., J.D. and D.M. are employed by Unity Biotechnology.

PowerPoint slides

Glossary

Senolysis

The therapeutic killing of senescent cells using small molecules (also known as senolytics).

Senescence

A tumour-suppressive cell fate undertaken in response to irreparable damage. It is characterized by permanent withdrawl from the cell cycle and acquisition of a pro-inflammatory, proteolytic secretome.

Senotherapies

Therapeutic strategies that aim to neutralize the deleterious effects of senescent cells as a treatment for age-related diseases.

Senescence-associated β-galactosidase

(SA-β-Gal). A lysosomal hydrolase with optimal activity at pH 6.0 in senescent cells (SNCs). Detection of SA-β-Gal enzymatic activity is frequently used to stain SNCs in vitro and in vivo.

Cyclin-dependent kinase inhibitor

(CDKi). A protein that arrests the cell cycle by binding to and deactivating cyclin-dependent kinases. p16INK4A, p19ARF, and p21 belong to this class of proteins and are commonly used as senescence markers.

Senescence-associated secretory phenotype

(SASP). The suite of secreted factors produced by senescent cells, including metalloproteinases, cytokines, chemokines, and growth factors, as well as non-protein metabolites.

Cytokines

Secreted protein factors that act as ligands for receptor- mediated cell signalling.

Chemokines

Cytokines, such as monocyte chemotactic protein 1 (MCP1), promote cellular migration (also known as chemotaxis).

BCL-2 family members

A protein class that consists of 25 members that share B cell lymphoma 2 (BCL-2) homology domains. These proteins either inhibit or promote mitochondrion-mediated apoptosis. BCL-2, BCL-W, and BCL-XL are three anti-apoptotic members that are inhibited by the senolytic and chemotherapeutic compound navitoclax.

High-mobility group box 1

(HMGB1). A member of a class of non-histone, chromatin proteins that modify transcription by binding to and distorting DNA. HMGB1 is released from senescent cells as an inflammatory 'alarmin'. Another member, HMGB2, is a positive regulator of senescence-associated secretory phenotype (SASP) factor transcription.

Metalloproteinases

A group of enzymes that cleave a peptide bond through the catalytic action of a coordinated metal ion (often zinc).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Childs, B., Gluscevic, M., Baker, D. et al. Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov 16, 718–735 (2017). https://doi.org/10.1038/nrd.2017.116

Download citation

Further reading